Janssen Pharmaceutical - New Long-Term Data from the CHRYSAL

CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a... | June 5, 2023

Related Keywords

United States , Chicago , Illinois , American , Hoon Lee , Kiran Patel , Samsung Medical Center , Clinical Development , Janssen Research , Johnson , Yuhan Corporation , American Society Of Clinical Oncology , Janssen Biotech Inc , Sungkyunkwan University School Of Medicine , Drug Administration , Janssen Pharmaceutical Companies , Janssen Research Development , Clinical Oncology , Medical Center , University School , Predictive Biomarkers , Lazertinib Combination , Safety Data , Investigational Use , Vice President , Solid Tumors , Response Evaluation Criteria , Solid Tumors Version , Blinded Independent Central Review , Practice Guidelines , Non Small Cell , Thoracic Oncology , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , News Publishing , Johnson Stock Exchange , News , Information , Press Release , The , Janssen , Harmaceutical , Companies , F , Oday , Nnounced , Results , Rom , Chrysalis , Which , Howed , Combination , Rybrevant , Nd Jnj Us4781601046 ,